Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1394 Novel oncolytic viral immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGFb-signaling while augmenting type-1 immune response in the tumor
Compose a Response to This Article
Other responses
No responses have been published for this article.
